India Ratings affirms Nectar Lifesciences’ long-term issuer rating at ‘A-’

26 Apr 2013 Evaluate

India Ratings & Research has affirmed Nectar Lifesciences’ long-term issuer rating at ‘A-’ with stable outlook.

The affirmation reflects the rating agency’s opinion that the company’s financial leverage (adjusted debt net cash/EBITDA) will see a sustained improvement over the medium term after deteriorating to 4.1x in FY12 (financial year ended March) from 3.3x in FY11.

Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.

Nectar Lifesciences Share Price

20.95 0.01 (0.05%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×